← Back to Home

Turning Rare Immune Cells Into an Off-the-Shelf Product: iPS Technology Overcomes the Mass-Production Barrier for γδ T Cells

A Kobe University team reprogrammed γδ T cells into iPS cells that can be expanded at scale, then produced immune cells capable of killing cancer; colorectal cancer models showed clear tumor suppression, but the evidence came from tumors from only two patients and a very small number of mice.

By SURL BioNews

For cell therapy to move beyond the model of “manufacturing separately for each patient,” the key lies not only in whether it can kill cancer cells, but also in whether enough cells can be produced reliably and quickly. A Kobe University research team has proposed a potential route to mass production: first reprogram rare γδ T cells into induced pluripotent stem cells (iPS cells) that can be expanded over the long term, then differentiate them back into T cells with antitumor function when needed.

γδ T cells recognize tumors differently from most conventional T cells. They are less dependent on tissue compatibility matching between patients and donors and can detect stress signals commonly found in cancer cells, making them a potential source material for “off-the-shelf” immunotherapy. However, these cells are scarce in the blood and are difficult to keep proliferating after collection, which has continued to constrain large-scale manufacturing.

The researchers converted donor γδ T cells into iPS cells, expanded them, and then regenerated γδ T cells, increasing the total number approximately 80,000-fold. The process did not use animal-derived cells or extracts, reducing the contamination and immune risks associated with xenogeneic components and bringing it closer to the conditions required for future clinical-grade production. The regenerated cells retained their ability to recognize and attack tumors and did not lose their original function through reprogramming.

The team tested the cells using organoids made from patient tumors and human colorectal cancers transplanted into mice. Compared with commonly used cancer cell lines, these models better preserve tumors’ drug resistance and physical barriers. The study reported that tumor growth was inhibited by approximately 70% to 100% in vitro and in some animal experiments; the cells also did not attack the tested healthy cells with mismatched tissue compatibility.

To simulate the treatment of metastatic cancer, the researchers also administered the cells intravenously one week after tumor implantation. In the three mice tested, tumor weight decreased by 43% to 92%, suggesting that the cells may reach tumors through systemic circulation. However, this set of results involved only three animals, each experiment included only three to four mice, and the tumor material came from two patients. Given the high heterogeneity of colorectal cancer, this is not yet sufficient to infer that the efficacy can be broadly reproduced.

The study, published in *Stem Cell Reports*, demonstrates a manufacturing method and preclinical feasibility at this stage, not efficacy in patients. Further work is still needed to confirm consistency across cell batches, persistence in the body, off-target damage, and the risk of tumor recurrence, as well as to expand testing to models derived from more patients and complete formal toxicology assessments. Only after these questions have been answered could the 80,000-fold expansion capacity truly translate into an off-the-shelf cell therapy suitable for clinical use.

References

  1. International Society for Stem Cell Research
  2. Kobe University
  3. Medical Xpress
  4. News-Medical.Net